Skip to main content
OpenTrials
Completed

NCT Number: NCT02043340

Single Session Of Antimicrobial Photodynamic Therapy Using Indocyanine Green

In recent years, there has been a growing interest in the use of dental lasers for treatment of periodontal diseases. Commercially available photodynamic therapy for periodontal diseases utilizes methylene blue as a photosensitizer. In this study, the effects of a novel photosensitizer dye, indocyanine green (ICG), as an adjunct to nonsurgical treatment of chronic periodontitis will be evaluated.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Periodontitis Mouth Diseases Periodontal Diseases Stomatognathic Diseases

Age range

30 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

About this study

Background and objective: Periodontal disease is caused by periodontal pathogens that colonize the dental plaque and the subsequent host-microbial interactions. The recent years have witnessed a rapid increase in the usage of Light Amplification by Stimulated Emission of Radiation (Laser) in dentistry for the treatment of periodontal diseases. The additive therapeutic effects when a photoactivated dye such as methylene blue is used in conjunction with Laser is well documented. Indocyanine green (ICG), a tri-carbocyanine that belongs to family of cyanine dyes is widely used in the fields of Ophthalmology and Cardiac imaging. Recent in vitro studies have reported its efficacy in killing potent periodontal pathogens like A. actinomycetemcomitans and P. gingivalis when combined with 810 nm diode laser. The present study aims at evaluating the effects of ICG as an adjunct to non-surgical treatment of chronic periodontitis in biofilm environment of human periodontal pockets in terms of immediate reduction in percentage of viable bacteria and at the same to quantitatively assess host tissue injury. Methods: The study included 30 patients diagnosed with chronic periodontitis. Three sites from three different quadrants were selected and assigned to three groups namely, SRP group - scaling and root planing, LASER group - scaling and root planing with application of 810 nm diode laser and ICG group - scaling and root planing with application of 810 nm diode laser and ICG at a concentration of 5 mg/mL. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients who were diagnosed with chronic periodontitis having a clinical evidence of periodontal pocket of ≥5mm, in at least 4 sites in each of the 3 quadrants.

  • Systemically healthy male & female patients within the age group of 35-55 years.
  • No history of medications affecting the periodontium (antibiotics, immunosuppressive drugs, anti-inflammatory, anti-oxidants, antibiotic tooth paste, mouthwashes) or periodontal therapy in the past 24 weeks period leading to the study.

Materials & Methods 26

  • Minimum of 5 teeth in each quadrant.

Exclusion criteria

Medically compromised patients.

  • Patients who had received any antibiotic, periodontal or laser therapy during the past 24 weeks of base line examination.
  • Patients using antibacterial mouth rinses or medicated tooth paste during the past 24 weeks.
  • Patients with history of tobacco chewing, smoking and alcohol consumption.
  • Pregnant women & lactating mothers.

Treatment and study plan

Indocyanine green

Drug

ICG group - scaling and root planing with application of 810 nm diode laser and ICG at a concentration of 5 mg/mL. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.

Other names: Cardiogreen, Photosensitizer

laser

Device

LASER group - scaling and root planing with application of 810 nm diode laser Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.

Other names: Diode LASER

Scaling and Root Planing

Procedure

SRP group - scaling and root planning. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.

Other names: Non-surgical Periodontal Therapy

Primary outcomes

  1. Bacterial Vitality

    Time frame: Baseline to 1 week

    Percentage of viable bacteria were estimated from the subgingival plaque samples at baseline, immediately after treatment and at the end of 1 week using a commercially available bacterial viability kit (LIVE/DEAD® BacLight™ Bacterial Viability Kit, Invitrogen, Leiden, The Netherlands).

Secondary outcomes

  1. LDH

    Time frame: Baseline to 1 week

    LDH activity is used as an indicator of relative cell viability and plasma membrane integrity.,28 Quantitative total LDH was assayed by using a commercially available kit (LDH-Cytotoxicity Assay Kit II (Colorimetric) ®, Abcam, Cambridge, MA, USA). Initially, 10 μL of mammalian cell lysis solution (Cell Lysis Solution, Abcam, Cambridge, MA, USA) was added to every 100 μL of the GCF collected which was subsequently incubated at 30ºC for 5 minutes. The manufacturer's instructions were subsequently followed and the absorbance at 450nm background after subtracting the zero well/NADH background from all readings was recorded by using a colorimetric microplate reader (iMark™ Microplate Absorbance Reader, Bio-Rad, Hyderabad, India). The results are expressed as total LDH activity (mUnits/site) per sample where one unit LDH is the amount of enzyme that catalyzes the conversion of lactate to pyruvate to generate 1.0 μmol to NADH per minute at 37°C.

Other outcomes

  1. Measures of Periodontal Health

    Time frame: Baseline to Six months

    Immediately after the laser application to the LASER group and 0.5 ml of 5mg/ml Indocyanine green dye along with laser to the ICG group by the second operator subgingival plaque samples were collected from the 3 sites by the first operator. The patients were recalled at the end of 1 week for collection of GCF and subgingival plaque samples for the assay of LDH levels and bacterial viability respectively. PI and MGI scores were recorded at the end of 1, 4, 12 and 24 weeks, while PD and CAL were recorded at the end of 12 and 24 weeks.

Sponsors and collaborators

Lead sponsor

SVS Institute of Dental Sciences

Other

Registry information

Official study title

Effect of A Single Session Of Antimicrobial Photodynamic Therapy Using Indocyanine Green In The Treatment Of Chronic Periodontitis

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Jan 23, 2014
Registry last updated
Jan 23, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.